STRESS-L is Suspended During COVID-19 Pandemic

As of 18 March 2020, STRESS-L has been temporarily halted to screening and recruitment until further notice. This decision has come following recent NIHR guidance to move towards supporting the Urgent Public Health research portfolio for COVID-19. The NIHR EME remain fully supportive of the trial and recruitment will recommence when are in the position to do so.

Sites are asked to move all IMP stored on ICU to pharmacy as soon as possible to ensure essential temperature monitoring continues and inform the STRESS-L trial team when this has been completed.

We ask recruitment sites to continue with essential safety reporting for STRESS-L patients and to suspend all other trial activity. The STRESS-L trial team will suspend all non-urgent requests to recruitment sites during this time. We do not wish to pose any burden on research staff during this time but if recruitment sites feel they have capacity to continue with data queries during this time please let the STRESS-L trial team know and we will continue to work through these with you.

Thank you to all of our recruitment sites for your hard work on the STRESS-L trial. We look forward to working with you again soon. Best wishes to all.

340 Patients
31 % Complete
Suspended to Recruitment
107

107 Patients Recruited

Thank you to our Patients, Relatives and Sites.

Now Open to 37 Sites

Our latest Site Visit was to Wolverhampton.

Suspended

Stress-L on Twitter

Follow Us - with the Handle ‎@StressLTrial

Separator Image of Stethoscope

About the Trial

Septic shock (sometimes called blood poisoning) is a life-threatening condition caused by severe infection. For reasons still poorly understood, in some patients, the inflammation in their system doesn’t reduce after an infection. Instead of fighting the infection, an ongoing inflammatory state results in widespread injury to the body and failure of normal functioning of the body’s vital organs, such as the lungs, heart, brain and kidneys. A common indicator of septic shock is a very low blood pressure that does not improve, even when treated with an intravenous fluid drip, which is the usual treatment for very low blood pressure.

 

For many years, we have routinely used in clinical practice a group of drugs known as ‘catecholamines’ to increase the patient’s blood pressure back to normal. The objective is that this will help their vital organs to function properly and to recover. The most commonly used catecholamine is noradrenaline, a synthetic form of a hormone produced by the body to deal with stressful situations. However, noradrenaline does carry side-effects when given at high doses and for extended periods of time, including adverse effects on the heart, immune system and metabolism. Thus, whilst the drug treatment given to help the body’s own production of these hormones may achieve the short-term goal of increasing blood pressure, it may be at the expense of more damage to the body. The use of catecholamines is therefore being questioned.

 

In 2013, a doctor called Morelli showed that when patients were being treated with a very high dose of noradrenaline, were also given a beta blocker (a type of drug that reduces the heart rate), patients on average got better more often, more quickly. We propose to repeat their study in multiple (approx. 45) intensive care units throughout the UK to see if we can confirm the safety and benefits of using beta blockers. We are also going to take blood samples to measure effects of the beta blocker on the patient’s immune system, metabolism and heart function so that we may better understand how it works. We also propose to store blood samples for analysis of the genes and proteins that may predispose patients to become so severely septic and to identify those who respond better to beta blocker therapy.

 

So what's this all about?

According to the UK Sepsis TrustOpens in New Window, septic shock kills 37,000 patients per year on wards and ICUs in the UK (more than bowel cancer, breast cancer and prostate cancer put together). Yet despite huge research efforts over the last 20-30 years, the death rate from this most severe manifestation of sepsis has remained unchanged. Outcomes have improved for sepsis in general through earlier recognition and intervention with antibiotics, however once the patient is in established shock, the risk of dying remains very high.

Continue Reading